Discovery and optimization of a novel Neuromedin B receptor antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4264-4267

  Fu, Jiasheng ^a   Shuttleworth, Stephen J ^a   Connors, Richard V ^a   Chai, Anne ^a   Coward, Peter ^a  

^a AMGEN INC   (United States)

Author keywords

Antagonist; Ary hexahydro dibenzodiazepin 1 one; NMBR; Parallel synthesis

Indexed keywords

ARY HEXAHYDRO DIBENZODIAZEPIN 1 ONE; BENZODIAZEPINE DERIVATIVE; NEUROMEDIN B; NEUROMEDIN B RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL;

ANIMALS; BENZODIAZEPINONES; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ELECTRONS; GASTRIN-RELEASING PEPTIDE; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, CHEMICAL; PEPTIDES; RECEPTORS, BOMBESIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649965567     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.124     Document Type: Article

References (29)

1. Moody T., and Jensen R.T. Drugs Future 23 (1998) 1305
2. Wada E., Way J., Shapira H., Kusano K., Lebacq-Verheyden A.M., Coy D., Jensen R., and Battey J. Neuron 6 (1991) 421
3. Spindel E.R., Giladi E., Brehm P., Goodman R.H., and Segerson T.P. Mol. Endocrinol. 4 (1990) 1956
4. Fathi J., Corjay M.H., Shapira H., Wada E., Benya R., Jensen R., Viallet J., Sausville E.A., and Battey J.F. J. Biol. Chem. 268 (1993) 5979
5. Minamino N., Kangawa M., and Matsuo H. Biochem. Biophys. Res. Commun. 114 (1983) 541
6. McDonald T.J., Jornvall J., and Nilsson G. Biochem. Biophys. Res. Commun. 90 (1979) 227
7. Brown M.R., Carver K., Fisher L.A., and Fisher L.A. Ann. N.Y. Acad. Sci. 547 (1988) 174
8. McCoy J.G., and Avery D.D. Peptides 11 (1990) 595
9. Albers H.E., Liou S.Y., Stopa E.G., and Zoeller R.T. J. Neurosci. 11 (1991) 846
10. Shumyatsky G.P., Tsvetkov E., Malleret G., Vronskaya S., Hatton M., Hampton L., Battey J.F., Dulac C., Kandel E.R., and Bolshakov V.Y. Cell 111 (2002) 905
11. Merali Z., Bédard T., Andrews N., Davis B., McKnight A.T., Gonzalez M.I., Pritchard M., Kent P., and Anisman H.J. Neuroscience 26 (2006) 10387
12. DelaFuente M., Delrio M., and Hernanz A. J. Neuroimmunol. 48 (1993) 143
13. Tache Y., Melchiorri P., and Negri L. Ann. N.Y. Acad. Sci. 517 (1988) 1
14. Gonzalez N., Moody T.W., Igarashi H., and Jensen R.T. Curr. Opin. Endocrinol Diabetes Obes. 15 (2008) 58
15. Shuttleworth S.J., Lizarzaburu M.E., Chai A., and Coward P. Bioorg. Med. Chem. Lett. 14 (2004) 3037
16. Eden J.M., Hall M.D., Higginbottom M., Horwell D.C., Howson W., Hughes J., Jordan R.E., Lewthwaite R.A., Martin K., McKnight A.T., O'Toole J.C., Pinnock R.D., Pritchard M.C., Suman-Chauban N., and Williams S.C. Bioorg. Med. Chem. Lett. 6 (1996) 2617
17. 6 transfected cells in Dulbeco's Modified Eagle Media (Mediatech, Inc.) in 100 μL in 96 well plates. Bound ligand was separated from unbound ligand by filtration using a Filtermate (Packard) and total counts bound determined on a TopCount NTX reader (Packard). Standard error of the assay day-to-day was <30%; well-to-well variability was <10%.
18. Sternbach L.H. J. Med. Chem. 22 (1979) 1
19. Blache Y., Benezech V., Chezal J.-M., Boule P., Viols H., Chavignon O., Teulade J.-C., and Chapat J.-P. Heterocycles 53 (2000) 905
20. Cortés E.C., Sanabria A.M.H., and Mellado O.G. J. Heterocycl. Chem. 39 (2002) 55
21. Cortés E.C., Sanabria A.M.H., and Mellado O.G. J. Heterocycl. Chem. 41 (2002) 277
22. Joseph B., Bethard A., Lesur B., and Guillaumet G. Synlett 10 (2003) 1542
23. Cortes C.E., Hernandez S.A.M., and Garcia M.O. J. Heterocycl. Chem. 39 (2002) 55
24. Castanedo G.M., Sailes F.C., Dubree N.J.P., Nicholas J.B., Caris L., Clark K., Keating S.M., Beresini M.H., Chiu H., Fong S., Marsters Jr. J.C., Jackson D.Y., and Sutherlin D.P. Bioorg. Med. Chem. Lett. 12 (2002) 2913
25. 1H NMR.
26. 3OH).
27. 2O requires 426.5.
28. Protocol for cytotoxicity assay: HeLa cells were seeded at 5 k/well in a 96 well plate (6 plates-for triplicate 0 and 72 h readings). A threefold dilution series of each compound was generated, starting at 10 mM. The solution was diluted eight times to prepare 9 concentrations ranging from 10 mM to 150 nM. Compound was added to cells (1-100 μL total volume), and the final concentration of compound was 100 μM to 15 nM. Zero and 72 h time points were recorded as follows: (a) 10 μL Alamar Blue reagent was added to the wells, and the samples were incubated at 37 °C for 3 h; (b) fluorescence intensity was then recorded on an LJL Analyst. The relative growth was compared to a DMSO control well for each compound.
29. 3H]Inositol (82.0 Ci/mmol, Amersham Pharmacia Biotech) overnight at 37 °C. Test compounds were then added in inositol-free DMEM containing 0.3% BSA (Sigma) and 10 mM LiCl (Sigma) for 60 min at 37 °C. The cells were lysed with 20 mM formic acid for 2 h at 4 °C and added to RNA-binding Ysi scintillation proximity assay beads (Amersham Pharmacia Biotech) for 30 min. Plates were stored overnight at room temperature in the dark and read the next day on a TopCount NTX.